Get the latest news, insights, and market updates on CARL (Carlsmed, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting
First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch WorkshopCARLSBAD, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo® Technology Platform for cervical fusion surgeries. Surgeons involved in the clinical evaluation will also present early clinical data at the Cervical Spine Research Society (CSRS) Dec 3, 2025 - $CARL
Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance
Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025. "We delivered another strong quarter with 98% revenue growth year-over-year, exp Nov 6, 2025 - $CARL
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before th Oct 23, 2025 - $CARL
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary
CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective immediately. Ms. Kamocsay will serve as legal counsel for the Company and oversee compliance and corporate governance. Ms. Kamocsay brings more than two decades of corporate legal experience as in- Sep 29, 2025 - $CARL
Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index
CARLSBAD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that effective after market close on September 22, 2025, it has been added to the Russell 2000® Index. This was part of the planned additions of select companies to this Index that had their IPO in the third quarter of 2025. “Carlsmed’s inclusion in the Russell 2000 Index is furth Sep 22, 2025 - $CARL
Here’s Goldman Sachs’ Next S&P 500 Target — Plus 2 Top Stock Picks
The stock markets are at record highs, having shown a solid recovery from their sharp losses in April. Year-to-date, the S&P 500 is up 11% and the NASDAQ is up 13.5%, reflecting continued positive sentiment. Against this backdrop, David Kostin, chief US equity strategist for Goldman Sachs, has summed up the current situation and laid out his predictions for the coming months. “As the economy moves through the worst of the tariff impacts we expect imminent Fed rate cuts and a re-acceleration of g Sep 12, 2025 - $CARL
Carlsmed® Reports Second Quarter 2025 Financial Results
Q2’25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the second quarter ended June 30, 2025. “Our strong commercial performance was driven by the continued adoption of our highly differentiated AI-enabled aprevo® technolo Aug 28, 2025 - $CARL
UPDATE - Carlsmed® Reports Second Quarter 2025 Financial Results
Q2’25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the second quarter ended June 30, 2025. “Our strong commercial performance was driven by the continued adoption of our highly differentiated AI-enabled aprevo® technolo Aug 28, 2025 - $CARL
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple